DBM
MCID: LKM056
MIFTS: 52

Leukemia, Chronic Lymphocytic 2 (DBM)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Leukemia, Chronic Lymphocytic 2

MalaCards integrated aliases for Leukemia, Chronic Lymphocytic 2:

Name: Leukemia, Chronic Lymphocytic 2 57
Leukemia, Chronic Lymphocytic, Susceptibility to, 2 57 28 12
B-Cell Malignancy, Low-Grade 57 71
Leukemia, Chronic Lymphocytic, B-Cell 57
Lymphocytic Leukemia Chronic B-Cell 53
Disrupted in B-Cell Malignancy 57
Chronic Lymphocytic Leukaemia 33
Chronic Lymphocytic Leukemia 71
Chronic Lymphatic Leukaemia 33
Lymphoplasmacytic Leukaemia 33
Chronic Lymphoid Leukaemia 33
Chronic Lymph Leukaemia 33
Clls2 57
Bcll 57
Dbm 57

Characteristics:


Inheritance:

Autosomal dominant 57

Classifications:



External Ids:

OMIM® 57 109543
ICD10 31 C91.1
MedGen 40 C1868683
SNOMED-CT via HPO 69 277473004 51092000 92814006
ICD11 33 1726842351
UMLS 71 C0023434 C1868683

Summaries for Leukemia, Chronic Lymphocytic 2

MalaCards based summary: Leukemia, Chronic Lymphocytic 2, also known as leukemia, chronic lymphocytic, susceptibility to, 2, is related to chronic lymphocytic leukemia/small lymphocytic lymphoma and b-cell non-hodgkin lymphoma, and has symptoms including fatigue, angina pectoris and chest pain. An important gene associated with Leukemia, Chronic Lymphocytic 2 is CLLS2 (Disrupted In B-Cell Neoplasia), and among its related pathways/superpathways are Hematopoietic Stem Cells and Lineage-specific Markers and Interleukin-4 and Interleukin-13 signaling. The drugs Valganciclovir and Rituximab have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and b cells, and related phenotypes are chronic lymphatic leukemia and immune system

More information from OMIM: 109543

Related Diseases for Leukemia, Chronic Lymphocytic 2

Diseases in the Leukemia, Chronic Lymphocytic family:

Leukemia, Chronic Lymphocytic 2 Leukemia, Chronic Lymphocytic 1
Leukemia, Chronic Lymphocytic 3 Leukemia, Chronic Lymphocytic 4
Leukemia, Chronic Lymphocytic 5 Adult Acute Lymphocytic Leukemia

Diseases related to Leukemia, Chronic Lymphocytic 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 554)
# Related Disease Score Top Affiliating Genes
1 chronic lymphocytic leukemia/small lymphocytic lymphoma 31.6 ZAP70 CD5 CD38 BCL2
2 b-cell non-hodgkin lymphoma 30.5 MS4A1 ATM
3 chromosome 13q14 deletion syndrome 30.5 ZAP70 CD5 CD38 ATM
4 burkitt lymphoma 30.2 MS4A1 FCER2 BCL2 ATM
5 marginal zone b-cell lymphoma 30.1 CD5 CD38 BCL2
6 lymphoma, mucosa-associated lymphoid type 30.1 ZAP70 CD5 BCL2
7 chromosomal triplication 30.1 ZAP70 BCL3
8 anemia, autoimmune hemolytic 30.0 ZAP70 CD5 CD38
9 prolymphocytic leukemia 29.9 ZAP70 MS4A1 FCER2 CD5 CD38 ATM
10 t-cell prolymphocytic leukemia 29.9 CD5 ATM
11 leukemia, acute lymphoblastic 29.9 ZAP70 MCL1 CD5 CD38 BCL2
12 lymphoplasmacytic lymphoma 29.8 CD5 CD38 BCL2
13 mantle cell lymphoma 29.8 ZAP70 MCL1 CD5 CD38 BCL2 ATM
14 bone lymphoma 29.8 CD5 BCL2
15 b-cell expansion with nfkb and t-cell anergy 29.8 ZAP70 MS4A1 FCER2 CD5 CD38
16 composite lymphoma 29.7 CD5 BCL2
17 plasmacytoma 29.6 CD5 CD38 BCL2
18 waldenstroem's macroglobulinemia 29.5 ZAP70 MS4A1 IGHM CD5 CD38
19 follicular lymphoma 29.4 MS4A1 MCL1 IGHM FCER2 CD5 BCL2
20 anaplastic large cell lymphoma 29.3 MCL1 BCL3 BCL2
21 mature b-cell neoplasm 29.3 MCL1 CD5 CD38 BCL2
22 richter's syndrome 29.2 ZAP70 CD5 CD38 BCL2 ATM
23 myeloma, multiple 29.0 MCL1 CD38 BCL2 ATM
24 immune deficiency disease 28.9 ZAP70 MS4A1 CD5 CD38 ATM
25 leukemia, acute myeloid 28.9 MCL1 CD5 CD38 BCL2 ATM
26 leukemia 28.5 ZAP70 MCL1 CD38 BCL3 BCL2 ATM
27 lymphoma, hodgkin, classic 28.3 ZAP70 MS4A1 MCL1 BCL3 BCL2 ATM
28 lymphoma, non-hodgkin, familial 28.0 MS4A1 MCL1 FCER2 CD5 CD38 BCL3
29 lymphoma 27.9 MS4A1 MCL1 CD5 CD38 BCL3 BCL2
30 b-cell lymphoma 27.8 ZAP70 MS4A1 MCL1 FCER2 CD5 BCL3
31 leukemia, chronic lymphocytic 26.8 ZAP70 MS4A1 MCL1 IGHM FCER2 CLLS2
32 neutropenia 10.9
33 thrombocytopenia 10.7
34 chromosome 17p deletion 10.7
35 b-cell prolymphocytic leukemia 10.7
36 diarrhea 10.6
37 factor vii deficiency 10.6
38 kidney disease 10.5
39 jacobsen syndrome 10.5
40 myelodysplastic syndrome 10.5
41 glomerulonephritis 10.5
42 telangiectasis 10.5
43 ataxia-telangiectasia 10.4
44 aplastic anemia 10.4
45 pancytopenia 10.4
46 graft-versus-host disease 10.4
47 tatton-brown-rahman syndrome 10.4
48 acute kidney failure 10.4
49 exanthem 10.4
50 skin squamous cell carcinoma 10.4

Graphical network of the top 20 diseases related to Leukemia, Chronic Lymphocytic 2:



Diseases related to Leukemia, Chronic Lymphocytic 2

Symptoms & Phenotypes for Leukemia, Chronic Lymphocytic 2

Human phenotypes related to Leukemia, Chronic Lymphocytic 2:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 chronic lymphatic leukemia 30 HP:0005550

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Oncology:
b-cell chronic lymphocytic leukemia (cll)

Clinical features from OMIM®:

109543 (Updated 08-Dec-2022)

UMLS symptoms related to Leukemia, Chronic Lymphocytic 2:


fatigue; angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Leukemia, Chronic Lymphocytic 2:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.65 ATM BCL2 BCL3 CD38 CD5 FCER2
2 hematopoietic system MP:0005397 9.32 ATM BCL2 BCL3 CD38 CD5 FCER2

Drugs & Therapeutics for Leukemia, Chronic Lymphocytic 2

Drugs for Leukemia, Chronic Lymphocytic 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 422)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
2
Rituximab Approved Phase 4 174722-31-7
3
Chlorambucil Approved Phase 4 305-03-3 2708
4 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
5 Antineoplastic Agents, Immunological Phase 4
6
Epoetin Alfa Phase 4
7 Hematinics Phase 4
8 Chrysarobin Phase 4
9
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
11
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
12
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
13
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
14
Iron Approved Phase 3 7439-89-6 29936
15
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2
16
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
17
Acalabrutinib Approved, Investigational Phase 3 1420477-60-6 71226663 71226662
18
Fludarabine Approved Phase 3 75607-67-9, 21679-14-1 30751 657237
19
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
20
Vidarabine Approved, Investigational Phase 3 24356-66-9 21704
21
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
22
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
23
Pancrelipase Approved, Investigational Phase 3 53608-75-6 8519
24
Lenograstim Approved, Investigational Phase 3 135968-09-1
25
Mitoxantrone Approved, Investigational Phase 3 70476-82-3, 65271-80-9 4212
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
27
Tenofovir Experimental, Investigational Phase 3 147127-20-6, 202138-50-9 464205 6398764
28 Reverse Transcriptase Inhibitors Phase 3
29 Cyclosporins Phase 3
30 Antifungal Agents Phase 3
31 Ferric Oxide, Saccharated Phase 3
32 Antirheumatic Agents Phase 3
33 Alkylating Agents Phase 3
34 Antineoplastic Agents, Alkylating Phase 3
35 Immunosuppressive Agents Phase 3
36 Immunologic Factors Phase 3
37 Antimetabolites Phase 3
38 Anti-Infective Agents Phase 3
39 Antiviral Agents Phase 3
40 Folic Acid Antagonists Phase 3
41 Folate Phase 3
42 Vitamin B9 Phase 3
43 Vitamin B Complex Phase 3
44 Caseins Phase 2, Phase 3
45
Triamcinolone hexacetonide Phase 3
46
Triamcinolone diacetate Phase 3
47
Triamcinolone Acetonide Phase 3 6436
48 Immunoglobulin G Phase 3
49 Liver Extracts Phase 3
50 Paraproteins Phase 3

Interventional clinical trials:

(show top 50) (show all 1243)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
3 A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
4 A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
5 Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study Completed NCT01255644 Phase 4 Valganciclovir
6 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
7 A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma Active, not recruiting NCT04930536 Phase 4 Acalabrutinib capsule
8 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Active, not recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
9 Long Term Effect on Immune Response After Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukemia and Evaluation of the Effect of Revaccination Active, not recruiting NCT05316831 Phase 4
10 Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens Not yet recruiting NCT04790045 Phase 4 Venetoclax
11 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
12 Prospective Randomized Study to Compare Efficacy and Safety of RFC-Lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status Terminated NCT01283386 Phase 4 Chlorambucil;Cyclophosphamide;Fludarabine;Rituximab
13 Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
14 A Randomised Investigation of Alternative Ofatumumab-containing Regimens in Less Fit Patients With CLL Unknown status NCT01678430 Phase 3 Ofatumumab;Chlorambucil;Bendamustine
15 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Unknown status NCT02991638 Phase 3 Ibrutinib
16 Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
17 Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3) Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
18 Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
19 A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Unknown status NCT02186574 Phase 3 Tenofovir disoproxil;Placebo Oral Tablet
20 A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL Unknown status NCT02475681 Phase 3 Acalabrutinib;Obinutuzumab;Chlorambucil
21 Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
22 Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia Completed NCT00281918 Phase 3 Rituximab;Cyclophosphamide;Fludarabine Phosphate
23 An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy Versus Physicians' Choice in Patients With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukaemia (CLL) Completed NCT01313689 Phase 3 Ofatumumab;Physicians' Choice
24 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
25 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
26 A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
27 Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO Completed NCT00645606 Phase 3
28 Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL) Completed NCT02756611 Phase 3 Venetoclax
29 A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia Completed NCT00824265 Phase 3 OFC Infusion;FC infusion
30 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial) Completed NCT00774345 Phase 3 Lenalidomide;Placebo
31 A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia Completed NCT01892618 Phase 3 Prevenar 13;Pneumovax
32 A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07 Completed NCT02049515 Phase 3 IPI-145 (duvelisib);Ofatumumab
33 A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT02264574 Phase 3 Ibrutinib;Obinutuzumab;Chlorambucil
34 A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With Mabthera (Rituximab) Versus No Treatment, After Induction Treatment With Rituximab, Cladribine and Cyclophosphamide (RCC) on Progression-Free Survival in Previously Untreated Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00718549 Phase 3 Cladribine;Cyclophosphamide;Rituximab
35 A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO) Completed NCT02004522 Phase 3 Duvelisib;Ofatumumab
36 A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia Completed NCT01905943 Phase 3 Bendamustine;Chlorambucil;Cyclophosphamide;Fludarabine;Obinutuzumab
37 A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab Completed NCT02005471 Phase 3 Bendamustine;Venetoclax;Rituximab
38 Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL) Completed NCT02980731 Phase 3 Venetoclax
39 A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) Completed NCT02301156 Phase 3 Ublituximab;Ibrutinib
40 A Prospective Case Series of Subcutaneous Immunoglobulin for Prophylaxis of Infections in Patients With Chronic Lymphocytic Leukemia With Impaired Humoral Immunity Completed NCT03730129 Phase 2, Phase 3 Hizentra
41 Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3 Fludarabine;Chlorambucil
42 Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity Completed NCT00281892 Phase 3 Fludarabine mono
43 Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
44 A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia Completed NCT00254163 Phase 3 Fludarabine;Cyclophosphamide;Rituximab;Pentostatin
45 Fludarabine Versus Fludarabine Plus Cyclophosphamide in First Line Therapy of Younger Patients (Up to 65 Years) With Advanced Chronic Lymphocytic Leukemia (CLL) Completed NCT00276848 Phase 3 Fludarabine plus Cyclophosphamide;Fludarabine
46 Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Completed NCT00024440 Phase 3 cyclophosphamide;fludarabine phosphate
47 Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
48 Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00003764 Phase 3 cyclophosphamide;fludarabine phosphate
49 International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia Completed NCT01118234 Phase 3 Rituximab
50 A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab

Search NIH Clinical Center for Leukemia, Chronic Lymphocytic 2

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alemtuzumab
Chlorambucil
Cladribine
Cyclophosphamide
etoposide phosphate
fludarabine
Fludarabine phosphate
Ibrutinib
Ifosfamide
Immunoglobulins, Intravenous
mercaptopurine
pegaspargase
Uracil Mustard

Genetic Tests for Leukemia, Chronic Lymphocytic 2

Genetic tests related to Leukemia, Chronic Lymphocytic 2:

# Genetic test Affiliating Genes
1 Leukemia, Chronic Lymphocytic, Susceptibility to, 2 28

Anatomical Context for Leukemia, Chronic Lymphocytic 2

Organs/tissues related to Leukemia, Chronic Lymphocytic 2:

MalaCards : T Cells, Bone Marrow, B Cells, Myeloid, Lymph Node, Nk Cells, Bone

Publications for Leukemia, Chronic Lymphocytic 2

Articles related to Leukemia, Chronic Lymphocytic 2:

(show top 50) (show all 4752)
# Title Authors PMID Year
1
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. 57
21205967 2011
2
Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. 57
9205107 1997
3
Evidence for a new tumour suppressor locus (DBM) in human B-cell neoplasia telomeric to the retinoblastoma gene. 57
8490658 1993
4
The Bcl-2 family as a rational target for the treatment of B-cell chronic lymphocytic leukaemia. 53 62
20156175 2010
5
Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. 53 62
19751240 2009
6
ZAP-70 and Syk expression in canine lymphoid cells and preliminary results on leukaemia cases. 53 62
19144411 2009
7
TRAIL receptors in the serum of patients with B-cell chronic lymphocytic leukemia. 53 62
18190241 2008
8
ZAP-70 and CD38 expression are independent prognostic factors in patients with B-cell chronic lymphocytic leukaemia and combined analysis improves their predictive value. 53 62
18519230 2008
9
What do somatic hypermutation and class switch recombination teach us about chronic lymphocytic leukaemia pathogenesis? 53 62
16323428 2005
10
[Some genomic aberrations in B-cell chronic lymphocytic leukemia and their clinical relevance. Part I. B-cell lymphocytic leukemia with TP53 gene deletion]. 53 62
15052934 2003
11
Interferon-alpha, Bcl-2 expression and apoptosis in B-cell chronic lymphocytic leukemia. 53 62
8907268 1996
12
Alterations of multiple tumor suppressor genes (p53 (17p13), p16INK4 (9p21), and DBM (13q14)) in B-cell chronic lymphocytic leukemia. 53 62
7576105 1995
13
Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene. 62
35333703 2022
14
Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation. 62
36454275 2022
15
Necrotizing herpes simplex lymphadenitis in a patient with chronic lymphocytic leukaemia/small lymphocytic lymphoma, clinically masquerading as Richter transformation. 62
35811089 2022
16
Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France. 62
36204003 2022
17
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. 62
36017875 2022
18
Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. 62
36354020 2022
19
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. 62
36400069 2022
20
SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions. 62
35970756 2022
21
Low CD49d expression in newly diagnosed chronic lymphocytic leukaemia may be associated with high-risk features and reduced treatment-free-intervals. 62
35776688 2022
22
Clinicopathological characteristics of individuals with coexisting melanoma and chronic lymphocytic leukaemia: a multicentre cohort study. 62
35801421 2022
23
Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)? 62
36100641 2022
24
ATM serine/threonine kinase germline mutations in chronic lymphocytic leukaemia come in different flavours. 62
36111522 2022
25
Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia. 62
36366824 2022
26
Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors. 62
36434612 2022
27
Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies. 62
36449134 2022
28
Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers. 62
36029002 2022
29
Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma. 62
36375473 2022
30
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. 62
35988545 2022
31
The evolving multi-agent options for chronic lymphocytic leukaemia treatment. 62
35988548 2022
32
Venetoclax activity in a patient with central nervous system involvement by chronic lymphocytic leukaemia. 62
36174642 2022
33
Cytomegalovirus DNAemia and disease: current-era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation. 62
34448333 2022
34
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. 62
35841338 2022
35
Acute myeloid leukaemia following direct acting antiviral drugs in HCV-infected patients: A 10 years' retrospective single-center study. 62
35933093 2022
36
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. 62
35466438 2022
37
Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. 62
36217114 2022
38
Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. 62
36273464 2022
39
Fibrillary and immunotactoid glomerulopathies in the Hunter region: a retrospective cohort study. 62
36305476 2022
40
No increased risk of mature B-cell non-Hodgkin lymphoma after Q fever detected: results from a 16-year ecological analysis of the Dutch population incorporating the 2007-2010 Q fever outbreak. 62
35352121 2022
41
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. 62
35861370 2022
42
Radiation and leukaemia: Which leukaemias and what doses? 62
36220737 2022
43
Blood-stained tears-a red flag for malignancy? 62
36088421 2022
44
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect. 62
36138486 2022
45
Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome. 62
35829664 2022
46
Sex-specific familial aggregation of cancers in Finland. 62
36068325 2022
47
Expression of BCL11A in chronic lymphocytic leukaemia. 62
36120992 2022
48
Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications. 62
36121003 2022
49
Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia. 62
35702012 2022
50
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. 62
36029036 2022

Variations for Leukemia, Chronic Lymphocytic 2

Expression for Leukemia, Chronic Lymphocytic 2

Search GEO for disease gene expression data for Leukemia, Chronic Lymphocytic 2.

Pathways for Leukemia, Chronic Lymphocytic 2

GO Terms for Leukemia, Chronic Lymphocytic 2

Biological processes related to Leukemia, Chronic Lymphocytic 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.8 MCL1 BCL3 BCL2 ATM
2 negative regulation of anoikis GO:2000811 9.76 MCL1 BCL2
3 oocyte development GO:0048599 9.73 BCL2 ATM
4 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.73 ATM BCL2 MCL1
5 negative regulation of T cell apoptotic process GO:0070233 9.71 BCL3 BCL2
6 T cell apoptotic process GO:0070231 9.67 BCL3 BCL2
7 response to cytokine GO:0034097 9.55 MCL1 CD38 BCL2
8 B cell proliferation GO:0042100 9.43 MS4A1 CD38 BCL2
9 B cell receptor signaling pathway GO:0050853 9.23 MS4A1 IGHM CD38 BCL2

Molecular functions related to Leukemia, Chronic Lymphocytic 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 BH3 domain binding GO:0051434 8.92 MCL1 BCL2

Sources for Leukemia, Chronic Lymphocytic 2

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....